Flash Finance

Metropolis Healthcare LimitedMETROPOLISCorporate

Healthcare Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹530.35
MCap ₹11,002 Cr · P/E 54.2
Metropolis Healthcare Limited — Stock analysis & AI research Metropolis Healthcare Limited — Seasonality — best & worst months Metropolis Healthcare Limited — Technical indicators & charts Metropolis Healthcare Limited — Technical setup — score, trend, support & resistance Metropolis Healthcare Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Low Debt Stocks 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹450 Cr
Sales · Jun 2026
+16.6% YoY
₹111 Cr
Operating Profit · Jun 2026
+23.9% YoY
24.7%
OPM % · Jun 2026
+6.5% YoY
₹57 Cr
Net Profit · Jun 2026
+25.7% YoY
₹2.73
EPS · Jun 2026
-68.6% YoY

📝 Metropolis Healthcare Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Metropolis Healthcare Limited reported revenue of ₹450 crore for the quarter ended June 2026 (Q1 FY27), up 16.6% from ₹386 crore in the same quarter last year, and up 6.0% sequentially over the March 2026 quarter.

Net profit rose 25.7% year-on-year to ₹57 crore, from ₹45 crore. Earnings per share (EPS) came in at ₹2.73.

Operating profit stood at ₹111 crore — an operating margin (OPM) of 24.7%, compared with 23.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Metropolis Healthcare Limited posted revenue of ₹1,646 crore, a growth of 23.6% over FY25, with a net profit of ₹191 crore (up 31.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,710 crore with a net profit of ₹203 crore.

Valuation snapshot

At the current price of ₹530.35, METROPOLIS has a market capitalisation of ₹11,002 crore and a trailing P/E of about 54.2.

Within the Healthcare industry, it is the 2nd-largest of the 22 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 48.86%, foreign institutional investors (FIIs) 11.03%, domestic institutional investors (DIIs) 35.12%, public shareholders 4.99% of Metropolis Healthcare Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹11,002 Cr
Current Price ?
₹530.4
P/E ?
54.25above ind
Industry P/E ?
34.70
P/B ?
7.27
P/S ?
6.43
P/FCF ?
36.67
Enterprise Value ?
₹11,234 Cr
EV/EBITDA ?
26.60
PEG ?
4.93
Earnings Yield ?
2.6%
Dividend Yield ?
0.38%
Profitability & Returns
Sales (TTM) ?
₹1,710 Cr
OPM ?
24.7%
Profit after tax (TTM) ?
₹203 Cr
EPS (TTM) ?
₹9.78
ROCE ?
18.0%
ROE ?
13.4%
ROA ?
9.5%
Growth
Sales — latest qtr ?
₹450 Cr
PAT — latest qtr ?
₹57 Cr
YoY qtr sales growth ?
16.6%
YoY qtr profit growth ?
25.7%
Sales growth (3y) ?
13%
Sales growth (5y) ?
11%
Profit growth (3y) ?
11%
Profit growth (5y) ?
1%
Financial Health
Debt ?
₹232 Cr
Debt to Equity ?
0.15
Interest Coverage ?
10.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
48.86%
Change in promoter holding ?
-0.03%
Pledged percentage ?
N/A
Market
Return 3 months ?
-2.7%
Return 6 months ?
12.4%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 283277308291331313350323345386429406425450 +16.6% +6.0%
Operating Profit 7063756580799072629010895108111 +23.9% +2.9%
Other Income 13123233781985 -32.1% -37.5%
Interest 66656555556686 +18.9% -22.1%
Depreciation 2321222526262728293132323932 +5.1% -16.0%
Profit Before Tax 4239483751516142366171577078 +26.9% +11.4%
Net Profit 3329362737384731294553425157 +25.7% +11.6%
EPS 6.511.411.731.337.117.419.086.125.698.7010.177.992.462.73 -68.6% +11.0%
OPM % 24.9% 22.7% 24.4% 22.3% 24.2% 25.2% 25.7% 22.3% 18.0% 23.2% 25.2% 23.4% 25.4% 24.7% +6.5% -2.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,331 Cr ₹1,646 Cr ₹1,710 Cr +23.6%
Operating Profit ₹303 Cr ₹401 Cr ₹422 Cr +32.3%
OPM % 22.76% 24.36% 24.69% +7.0%
NPM % 10.93% 11.62% 11.86% +6.3%
Other Income ₹15 Cr ₹26 Cr ₹23 Cr +69.2%
Depreciation ₹109 Cr ₹134 Cr ₹135 Cr +23.0%
Interest ₹19 Cr ₹25 Cr ₹26 Cr +32.2%
EBIT ₹194 Cr ₹267 Cr ₹287 Cr +37.5%
PBT ₹191 Cr ₹259 Cr ₹276 Cr +35.8%
Tax ₹45 Cr ₹68 Cr ₹73 Cr +50.0%
Net Profit ₹146 Cr ₹191 Cr ₹203 Cr +31.4%
EPS ₹28.30 ₹29.32 ₹23.35 +3.6%
Material Cost ₹273 Cr ₹335 Cr ₹338 Cr +22.7%
Employee Cost ₹314 Cr ₹377 Cr ₹392 Cr +20.3%
Extraordinary Items — ₹-9 Cr ₹-9 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 10101041 +310.0%
Reserves 9781,0861,3211,472 +11.4%
Borrowings 266197204232 +13.7%
Other Liabilities 240254324393 +21.3%
Total Liabilities 1,4951,5471,8592,138 +15.0%
Fixed Assets 1,1211,1771,4471,601 +10.6%
CWIP 20000 —
Investments 155571142 +100.0%
Other Assets 340316341395 +15.8%
Total Assets 1,4951,5471,8592,138 +15.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 247264263351 +33.5%
Cash from Investing Activity 48-89-199-223 -12.1%
Cash from Financing Activity -292-181-87-115 -32.2%
Net Cash Flow 3-6-2312 +152.2%
Free Cash Flow 195200196300 +53.1%
CFO/OP 102%105%99%99% +0.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
ROCE % 17%16%15%18% +20.0%
Debtor Days 39384138 -7.3%
Inventory Days 64586551 -21.5%
Days Payable 136150171146 -14.6%
Cash Conversion Cycle -33-53-65-57 +12.3%
Working Capital Days -22-16-1816 +188.9%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 48.89%48.89%48.87%48.86%48.86% +0.0%
FIIs 12.83%12.52%11.68%10.43%11.03% +5.8%
DIIs 32.40%33.10%34.73%35.80%35.12% -1.9%
Public 5.87%5.48%4.69%4.92%4.99% +1.4%
No. of Shareholders 50,01547,84646,67049,17550,636 +3.0%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Metropolis Healthcare Limited's revenue in Q1 FY27?
Metropolis Healthcare Limited reported revenue of ₹450 crore for the quarter ended June 2026 (Q1 FY27), up 16.6% from ₹386 crore in the same quarter last year, and up 6.0% sequentially over the March 2026 quarter.
What was Metropolis Healthcare Limited's net profit in Q1 FY27?
Net profit rose 25.7% year-on-year to ₹57 crore, from ₹45 crore. Earnings per share (EPS) came in at ₹2.73.
What is METROPOLIS's market capitalisation and P/E ratio?
At the current price of ₹530.35, METROPOLIS has a market capitalisation of ₹11,002 crore and a trailing P/E of about 54.2.
Who owns Metropolis Healthcare Limited? (shareholding pattern)
As of Jun 2026, promoters held 48.86%, foreign institutional investors (FIIs) 11.03%, domestic institutional investors (DIIs) 35.12%, public shareholders 4.99% of Metropolis Healthcare Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI